METASTATIC MALIGNANT SOLID NEOPLASM

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This early-phase trial tests two drugs—ZEN003694 and abemaciclib—together in people with advanced NUT carcinoma, breast cancer, or other solid tumors that have spread or can't be removed. The main goals are to find the safest dose and see if the combination can shrink or stabiliz…

This study tests a drug called durvalumab, which helps the immune system fight cancer, when given with standard chemotherapy. It is for people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combination is safe and how it aff…

This study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…

This early-stage study tests a new drug called MTI-301 in about 42 adults with advanced solid cancers that have spread or not responded to standard treatments. MTI-301 blocks an enzyme (SCD1) that helps tumors grow. The main goals are to find the safest dose and check for side ef…

This early-phase study tests a combination of two drugs (trastuzumab deruxtecan and azenosertib) in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and…

This early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find the safest dose and understand side effects. About 66 adults with specific genetic ch…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests the drug pemetrexed in people with metastatic bladder cancer or other solid tumors that have certain gene mutations (MLL4, UTX, or MTAP). The goal is to see if the drug can shrink tumors. About 64 adults will take pemetrexed and be monitored for response every 9 …

This early-stage trial tests CBX-12, a drug that damages cancer cell DNA to kill them, in about 35 adults with advanced or metastatic solid tumors that have worsened after at least one prior treatment. The main goal is to see how the drug affects DNA repair in tumors. This is not…

This early-phase study tests the safety and best dose of TAK-243, a drug that targets a protein cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma that hasn't responded to standard treatments will take part. The goal is to find side effects and the …

This early-phase study tests two drugs, DS-8201a and olaparib, together in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the best dose and see if the combination can shrink or stabilize tumors. About 55 adults with certain so…

This study tests a combination of two drugs, temozolomide and M1774, in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combo can shrink or slow tumor growth better than temozolomide alone. About 58 participants will take par…

This early-stage trial tests the safety and best dose of a new drug called ZEN003694 when given with the standard chemotherapy capecitabine. It is for adults with solid tumors that have spread or can't be removed and have not responded to prior treatments. The goal is to find a d…

This study tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation, combined with standard radiation and immunotherapy (anti-PD-1/L-1) for people with advanced solid tumors that have spread to the lungs or liver. The goal is to see if this combination…

This early-phase trial tests a personalized cell therapy for people with metastatic solid tumors that carry a specific genetic mutation (KRAS G12V). Patients' own immune cells are genetically modified to recognize and attack cancer cells. The study aims to find the safest dose an…

This study tests whether three targeted cancer drugs (antibody-drug conjugates) can shrink advanced solid tumors that have spread. Patients' tumors are screened for specific proteins (Trop-2, nectin-4, or HER2), and they receive the matching drug. The goal is to see if this perso…

This study tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and works against advanced or metastatic solid tumors. About 38 adults with tumors that have spread will receive the combination. The goal is to find the best dose and see if the treat…

This early-stage study tests a new chemotherapy drug, TR-002, in about 52 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. The study also looks at whether the drug can shr…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests a pill called larotrectinib in people with advanced solid tumors that have too many copies of the NTRK gene. The drug blocks enzymes that help cancer cells grow. About 13 participants will take the drug to see if their tumors shrink or stop growing.

This study tests whether combining two targeted drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have spread or cannot be removed. The trial enrolls 88 adults whose cancer no longer responds to standard treatments. Researchers will al…

This early-phase trial tests the safety and best dose of two drugs given together for people with advanced breast cancer or other solid tumors that have a protein called HER2. The drugs are pidnarulex (which stops cancer cells from repairing themselves) and trastuzumab deruxtecan…

This study tests the drug talazoparib in adults with advanced solid tumors (like breast, prostate, ovarian, pancreatic, or stomach cancer) that have certain gene changes affecting DNA repair. The drug blocks a protein called PARP, which cancer cells need to fix their DNA, potenti…

This early-stage study is testing a new method called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this approach is safe and can reduce side effects compared to standard chemotherapy. Abou…

This early-phase study tests a drug called novobiocin in people with advanced solid tumors that have specific DNA repair gene mutations (like BRCA). Novobiocin blocks a protein cancer cells need to fix their DNA, causing them to die. The goal is to find the safest dose and see if…

This early-phase trial tests the drug talazoparib combined with one of three other drugs (palbociclib, axitinib, or crizotinib) in people with advanced or metastatic solid tumors. The goal is to find the safest dose and see if the combinations help control tumor growth. About 111…

This early-stage study tests a new oral drug called pidnarulex in 40 adults with advanced solid tumors that have spread and stopped responding to standard treatments. The drug works by blocking a key enzyme cancer cells need to divide and repair their DNA. The main goal is to see…

This early-stage study tests a new type of radiation called biology-guided radiation therapy (BgRT) for people with cancer that has spread to the bone and causes pain. The treatment uses live imaging to target only the active tumor, aiming to provide pain relief with a single dos…

This study tests a parenting support program for parents with advanced cancer and their spouses. The program aims to reduce parenting worries, improve family communication about cancer, and boost emotional well-being. About 120 families with children ages 4 to 16 will take part.

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study tests whether giving radiation in three smaller doses (fractionated SRS) is better than a single large dose (standard SRS) for treating cancer that has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be enrolled. The goa…

This study tests whether freezing bone tumors (cryoablation) before giving radiation therapy works better than radiation alone for reducing pain. About 40 adults with cancer that has spread to the bones will be enrolled. The goal is to see if the combination provides more complet…

This study looks at two ways to deliver precise radiation to brain tumors that have spread from other cancers. One method gives all the radiation in a single session, while the other spreads it over several sessions. The goal is to find out which approach better controls the tumo…

This study tests whether a group retreat using psilocybin (the active ingredient in magic mushrooms) can safely reduce anxiety and depression in people with incurable cancer. Participants will take a pharmaceutical-grade psilocybin pill and take part in guided discussions. The go…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 therapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to und…

This early-phase trial studies how to best give arginine (a natural amino acid) alongside whole brain radiation for people whose cancer has spread to the brain. Researchers will compare oral and IV arginine to find the dose that reaches the highest blood levels. The goal is to le…

This study screens patients with advanced solid tumors to find genetic changes in their cancer cells. Based on those results, patients may be matched to a treatment trial that targets their specific tumor mutations. The goal is to improve how doctors choose combination therapies …

This study collects tissue samples from people with various advanced or early-stage cancers to train a new diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 partici…

This study collects tissue and blood samples from 5,000 cancer patients to create lab models, like patient-derived xenografts and cell lines. The goal is to help scientists better understand cancer and test new treatments. Participants must be over 2 months old and have a confirm…

This study tests a new PET scan that tracks immune cells called CD8+ T cells, which help fight cancer. Ten adults with lymphoma or metastatic solid tumors will get the scan before and after radiation therapy. The goal is to see if radiation brings more immune cells to tumors, not…